Cargando…

Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay

Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Borena, Wegene, Kimpel, Janine, Gierer, Melanie, Rössler, Annika, Riepler, Lydia, Oehler, Susanne, von Laer, Dorothee, Miholits, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229387/
https://www.ncbi.nlm.nih.gov/pubmed/34200301
http://dx.doi.org/10.3390/vaccines9060611
_version_ 1783712965120229376
author Borena, Wegene
Kimpel, Janine
Gierer, Melanie
Rössler, Annika
Riepler, Lydia
Oehler, Susanne
von Laer, Dorothee
Miholits, Markus
author_facet Borena, Wegene
Kimpel, Janine
Gierer, Melanie
Rössler, Annika
Riepler, Lydia
Oehler, Susanne
von Laer, Dorothee
Miholits, Markus
author_sort Borena, Wegene
collection PubMed
description Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex serological assay capable of detecting antibodies directed to four antigenic targets of SARS-CoV-2 and to S1 proteins of other human pathogenic coronaviruses. We used 620 well-characterized sera (n = 458 seropositive and n = 110 seronegative for SARS-CoV-2 in the pre-SARS-CoV-2 era and n = 52 seronegative for SARS-CoV-2 in the era of SARS-CoV-2) as positive and negative standards. We calculated the sensitivity, specificity, as well as positive and negative predictive values, including a 95% confidence interval. The difference in mean fluorescence intensity (95% CI) was used to assess a potential cross-reaction between antibodies to SARS-CoV-2 and the other coronaviruses. The sensitivity (95% CI) of detecting anti-SARS-CoV-2 antibodies to four antigenic targets ranged from 83.4% (76.7–86.7) to 93.7% (91.0–95.7) and the specificity from 98.2% (93.6–99.8) to 100% (96.7–100). We observed no obvious cross-reaction between anti-SARS-CoV-2 antibodies and antibodies to the other coronaviruses except for SARS-CoV-1. The high sensitivity and specificity warrant a reliable utilization of the assay in population-based seroprevalence surveys or vaccine efficacy studies.
format Online
Article
Text
id pubmed-8229387
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82293872021-06-26 Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay Borena, Wegene Kimpel, Janine Gierer, Melanie Rössler, Annika Riepler, Lydia Oehler, Susanne von Laer, Dorothee Miholits, Markus Vaccines (Basel) Article Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex serological assay capable of detecting antibodies directed to four antigenic targets of SARS-CoV-2 and to S1 proteins of other human pathogenic coronaviruses. We used 620 well-characterized sera (n = 458 seropositive and n = 110 seronegative for SARS-CoV-2 in the pre-SARS-CoV-2 era and n = 52 seronegative for SARS-CoV-2 in the era of SARS-CoV-2) as positive and negative standards. We calculated the sensitivity, specificity, as well as positive and negative predictive values, including a 95% confidence interval. The difference in mean fluorescence intensity (95% CI) was used to assess a potential cross-reaction between antibodies to SARS-CoV-2 and the other coronaviruses. The sensitivity (95% CI) of detecting anti-SARS-CoV-2 antibodies to four antigenic targets ranged from 83.4% (76.7–86.7) to 93.7% (91.0–95.7) and the specificity from 98.2% (93.6–99.8) to 100% (96.7–100). We observed no obvious cross-reaction between anti-SARS-CoV-2 antibodies and antibodies to the other coronaviruses except for SARS-CoV-1. The high sensitivity and specificity warrant a reliable utilization of the assay in population-based seroprevalence surveys or vaccine efficacy studies. MDPI 2021-06-07 /pmc/articles/PMC8229387/ /pubmed/34200301 http://dx.doi.org/10.3390/vaccines9060611 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Borena, Wegene
Kimpel, Janine
Gierer, Melanie
Rössler, Annika
Riepler, Lydia
Oehler, Susanne
von Laer, Dorothee
Miholits, Markus
Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title_full Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title_fullStr Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title_full_unstemmed Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title_short Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
title_sort characterization of immune responses to sars-cov-2 and other human pathogenic coronaviruses using a multiplex bead-based immunoassay
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229387/
https://www.ncbi.nlm.nih.gov/pubmed/34200301
http://dx.doi.org/10.3390/vaccines9060611
work_keys_str_mv AT borenawegene characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT kimpeljanine characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT gierermelanie characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT rosslerannika characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT rieplerlydia characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT oehlersusanne characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT vonlaerdorothee characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay
AT miholitsmarkus characterizationofimmuneresponsestosarscov2andotherhumanpathogeniccoronavirusesusingamultiplexbeadbasedimmunoassay